Equity Profile

PCVX

Vaxcyte, Inc.

Health CareBiotechnology$8.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Understanding revenue trends will provide insights into the company's market performance and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. With a market cap of $8 billion, Vaxcyte plays a crucial role in the healthcare sector, especially as the demand for effective vaccines continues to grow in response to global health challenges.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, missing estimates by nearly 24%. Despite the miss, the stock rose by 2.62% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Vaxcyte's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can improve its financial performance after recent misses.

Bull Case

If Vaxcyte can show significant progress in its vaccine development and improve its EPS, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company continues to report larger-than-expected losses and lacks clear guidance on revenue growth, it may face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on vaccine candidates in development?

Progress on vaccine development is crucial for investor confidence and future revenue potential.

How does Vaxcyte plan to address the recent trend of larger-than-expected losses?

Understanding management's strategy for improving financial performance will be key to market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Vaxcyte's potential for recovery, especially if they can demonstrate progress in their vaccine pipeline despite recent losses.

Supporting Evidence

Options are pricing a 22.18% move, indicating expectations of volatility that may not align with historical performance.

The company's recent stock price increases following disappointing earnings suggest underlying investor optimism.

Key Risk

If vaccine development shows significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether Vaxcyte can demonstrate a path to profitability amidst its ongoing vaccine development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improved financial health.

Bear Confirmed If

If EPS losses exceed -$2.50, it would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests the stock could rise by around 1.82%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess.

Miss

Should the company miss expectations again, history suggests a potential decline of around 0.06%, reflecting continued investor caution.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of vaccine candidates and timelines for potential approvals.
2Management's strategy for reducing EPS losses and improving financial health.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for Vaxcyte's vaccines and competitive positioning.
5Guidance on revenue expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Vaxcyte, Inc. (PCVX) is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Understanding revenue trends will provide insights into the company's market performance and product acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PCVX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.32%

Avg Stock Reaction

-0.06%

Last Quarter Recap

In Q1-2026, Vaxcyte reported an EPS of -$2.30, missing estimates by nearly 24%. Despite the miss, the stock rose by 2.62% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Vaxcyte can show significant progress in its vaccine development and improve its EPS, it could lead to a strong positive reaction from the market.

Bear Case

Conversely, if the company continues to report larger-than-expected losses and lacks clear guidance on revenue growth, it may face further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific updates can management provide on vaccine candidates in development?

Progress on vaccine development is crucial for investor confidence and future revenue potential.

How does Vaxcyte plan to address the recent trend of larger-than-expected losses?

Understanding management's strategy for improving financial performance will be key to market sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Vaxcyte's potential for recovery, especially if they can demonstrate progress in their vaccine pipeline despite recent losses.

Supporting Evidence

Options are pricing a 22.18% move, indicating expectations of volatility that may not align with historical performance.

The company's recent stock price increases following disappointing earnings suggest underlying investor optimism.

Key Risk

If vaccine development shows significant progress, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus will be on whether Vaxcyte can demonstrate a path to profitability amidst its ongoing vaccine development efforts.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate improved financial health.

Bear Confirmed If

If EPS losses exceed -$2.50, it would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.18%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±22.2% while PCVX has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

49.6%

Calls (100)P/C Ratio: 0.12Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vaxcyte beats expectations, history suggests the stock could rise by around 1.82%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess.

Miss

Should the company miss expectations again, history suggests a potential decline of around 0.06%, reflecting continued investor caution.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of vaccine candidates and timelines for potential approvals.
2Management's strategy for reducing EPS losses and improving financial health.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market demand for Vaxcyte's vaccines and competitive positioning.
5Guidance on revenue expectations for the upcoming quarters.